|
gptkbp:instanceOf
|
gptkb:nonsteroidal_anti-inflammatory_drug
gptkb:drug
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:M01AH01
|
|
gptkbp:availableOn
|
capsule
|
|
gptkbp:brand
|
gptkb:Celebra
gptkb:Celebrex
Onsenal
|
|
gptkbp:CASNumber
|
gptkb:169590-42-5
|
|
gptkbp:chemicalFormula
|
gptkb:pyrazole_derivative
|
|
gptkbp:contraindication
|
active gastrointestinal bleeding
history of allergic reaction to NSAIDs
hypersensitivity to sulfonamides
|
|
gptkbp:discoveredBy
|
gptkb:G.D._Searle_&_Company
|
|
gptkbp:drugClass
|
selective COX-2 inhibitor
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H14F3N3O2S
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:fluconazole
lithium
ACE inhibitors
diuretics
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:nonsteroidal_anti-inflammatory_drug
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
liver
|
|
gptkbp:patentExpired
|
2014
|
|
gptkbp:pregnancyCategory
|
D (US, third trimester)
C (US, first and second trimester)
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:riskFactor
|
increased risk of cardiovascular events
risk of gastrointestinal bleeding
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
headache
hypertension
gastrointestinal upset
|
|
gptkbp:synonym
|
gptkb:Celecoxibum
SC-58635
|
|
gptkbp:usedFor
|
osteoarthritis
pain
inflammation
rheumatoid arthritis
ankylosing spondylitis
primary dysmenorrhea
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NSAID
gptkb:Celebrex
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
celecoxib
|